Abstract
Introduction: Hepatitis C virus (HCV) infection is a major public health problem and may lead to liver failure and cancer. New direct-acting antiviral medications (DAAs) are potent with shorter course of treatment and less side effects. However, the cost of these medications and the limited experience are the main obstacles for their use. Case Presentation: Here, a sustained virological response (SVR) was achieved in a patient, who received interferon, ribavirin and sofosbuvir for six weeks. Medications were stopped at the sixth week of treatment due to severe depression and reduction in albumin levels. Conclusions: This report highlighted the importance of further studies to determine the safety and optimum duration of treatment with DAAs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
